wavePod

Get Wave AI

On tuberculosis (with John Green) - Drug Story | Wave AI Podcast Notes

Back to Drug Story

On tuberculosis (with John Green)

Drug Story

Tue Feb 17 2026

Summary

Podcast Summary: Drug Story – "On Tuberculosis" (with John Green)

Host: Thomas Goetz
Guests: John Green (author, YouTuber), Dan Weissman (host of An Arm and a Leg), Emily Pisacreta, Tahir Amin, Pumeza Tisile
Date: February 17, 2026

Episode Overview

This episode of Drug Story investigates the tangled history and present-day challenges of tuberculosis (TB)—with a particular focus on the life-saving drug bedaquiline, the corporate patent system, and the global movement attempting to make TB drugs affordable and accessible. The episode, hosted primarily by Dan Weissman and featuring bestselling author and advocate John Green, highlights how patients, lawyers, and a worldwide community of "nerdfighters" confronted pharmaceutical giant Johnson & Johnson over drug patents that restrict access to vital TB medication.

Key Discussion Points & Insights

1. The Power and Flaws of Drug Innovation

Historical Context of TB
- Host Thomas Goetz recounts the history of TB, referencing his book The Remedy:
  
  "Since Koch's discovery of the bacteria in 1882, more than a billion people have died of the disease, even with antibiotics. Even today, people die of TB—more than a million people a year." (01:40)
- TB's initial "cure" by Koch was debunked; true breakthroughs came with streptomycin (1943) and other antibiotics.
- Despite effective drugs, TB remains deadly, especially in Asia, Africa, and India.

2. John Green's TB Activism and Community Impact

Personal Connection and Storytelling
- John Green shares his experience visiting a TB hospital in Sierra Leone, where he met a child, "Henry," who was actually a 16-year-old stunted by TB and desperately needed access to bedaquiline.
  
  “He was just really stunted and emaciated by tuberculosis... if we can't get the new treatment cocktail to him, he has a very low chance of survival.” (12:20–13:19)
- This life-and-death encounter drove John Green’s obsession with tackling TB and its global inequities.
Mobilizing the Nerdfighters
- Green leveraged his online following to highlight that Johnson & Johnson was using secondary patents to keep monopolizing bedaquiline and thus keeping it out of reach for millions in poorer countries.
  
  "The only reason Johnson & Johnson executives think they can get away with this is that they think we aren't paying attention..." (04:37)
- Within a week, Johnson & Johnson responded by allowing a cheaper generic to be distributed more widely—a testament to advocacy’s power but also its limitations.

3. How Pharmaceutical Patenting Works Against Public Health

Patent Thicketing/Evergreening Explainer
- Emily Pisacreta and Tahir Amin explain how pharma companies file dozens (or even over a hundred) overlapping patents to extend exclusivity and maximize profits.
  
  “74 patents could have lasted until 2031.” (17:00) “The 12 best-selling drugs in the US had an average of 131 patents each. If all of those patents stick, that's an average of 38 years of patent protection.” – Tahir Amin (19:18)
- This "life cycle management" keeps drug prices high and generics off the market—impacting not only Americans but the entire world.
Bedaquiline’s Case
- Johnson & Johnson filed a secondary patent on a "salt formulation" of bedaquiline four years after the original, extending their monopoly.
  
  "The most important was the original formula... the second most important was the salt formulation..." (20:11)
- Filing secondary patents late in the drug development process is strategic; it delays generic competition.

4. India’s Legal Fight: Section 3D and Global Implications

Birth of Section 3D
- Indian activists and lawyers (notably Tahir Amin) secured a law stating additional patents for known drugs must show increased efficacy—making it harder for companies to "evergreen."
  
  “If you are going to try and patent a new formulation... you have to prove that it increases the drug’s efficacy…” – Emily Pisacreta (27:11)
- After years of legal struggle, in March 2023, India’s patent office rejected Johnson & Johnson’s secondary patent on bedaquiline, clearing the way for generic manufacture.
  
  "India rejected Johnson & Johnson’s secondary patent on bedaquiline." (31:01)
TB Survivors as Advocates
- Survivors like Pumeza Tisile and Nandita Venkateshan led the fight, bringing personal stakes to the legal battle.
  
  “Fumesa could see her lips moving, but couldn’t hear her voice... Like about half the people given this treatment, she lost her hearing for good.” (29:46)

5. The Global South's Influence on US Patent Thinking

Reverse Advocacy
- Global South’s strategies—like India’s Section 3D—are now informing advocacy efforts in the United States, aiming to reform the US patent landscape that still drives up global drug prices.
  
  “US drug companies shaped the World Trade Organization policies regarding drug patents, the policies that force places like India to recognize patents…” – Emily Pisacreta (37:08)
- IMak (Initiative for Medicines Access and Knowledge) has shifted its focus largely to US advocacy.

6. Reflection on Activism, Advocacy, and Hope

Incremental Gains Matter
- Both John Green and Tahir Amin note that progress can be slow, and no single victory is ever enough—each step forward matters.
  
  “It's like you’re trying to move the ocean and you have a little bucket… And I find a lot of beauty in that.” – John Green (40:16)
- Ultimately, activism needs both immediate direct action (such as the nerdfighter mobilization) and deep structural reform (legal and policy challenges).

Notable Quotes & Memorable Moments

On hope and powerlessness:

“I felt powerless before it... It was the first thing I thought about in the morning and the last thing I thought about before I went to sleep: How did we end up in a world where the world's deadliest infectious disease is largely ignored in the richest parts of the world?” – John Green (22:43–23:02)
On evergreening:

“Activists and experts call this kind of thing patent thicketing or evergreening... Drug companies call it life-cycle management.” – Dan Weissman (19:37–19:42)
On social benefits of patents:

"The social benefit actually goes up when you get the initial sort of a certain period of protection. But once you start stretching it out, the social benefit goes down." – Tahir Amin (37:56)
On global influence:

"The US is the heart of the global patent regime. US drug companies shaped the World Trade Organization policies... and it's U.S. patent officers who train examiners around the world." – Emily Pisacreta (37:08)
On incremental activism:

"It's like you're trying to move the ocean and you have a little bucket... but I am going to go ahead and fill up this bucket and walk a hundred feet and pour it in the ditch and then I'm going to walk back to the ocean... and I find a lot of beauty in that." – John Green (40:16)
On collective action:

"When tens of thousands of people do something insignificant together, it becomes very significant." – John Green (43:19)

Key Timestamps for Important Segments

00:01–03:40 – Thomas Goetz gives the history of TB and sets the stage for the episode and handoff to Dan Weissman/John Green.
03:45–08:09 – Dan Weissman introduces John Green and his online influence; background on the nerdfighter community.
10:41–13:19 – John Green recounts his visit to the TB hospital in Sierra Leone and the story of "Henry."
16:26–19:18 – Emily Pisacreta and Tahir Amin explain patent thicketing with insulin and other US drug examples.
20:11–21:57 – Technical discussion of bedaquiline’s salt formulation patent and patent strategies.
24:45–27:23 – History of India's Section 3D and its impact on drug patents.
29:03–31:40 – Fumesa Tisile’s account of her TB experience and the MSF-led legal challenge in India.
33:25–34:23 – John Green’s “Barely Contained Rage” video and its community impact.
36:12–39:11 – Tahir Amin on why India’s precedent must inform global and US patent reform.
40:16–41:14 – John Green’s reflection on movement-building and incremental change.
43:19 – John Green's call to action for collective bucket-moving activism.

Takeaways

The story of bedaquiline and TB is emblematic of the wider global fight over drug patents, access, profit, and innovation.
"Patent thickets" and evergreening practices keep essential drugs out of reach for millions—even when they could be produced cheaply.
Grassroots and legal advocacy, as seen in India and through John Green’s nerdfighter community, can create real (if limited) change.
Deep, systemic reform of the global patent regime, with lessons drawn from the Global South, is necessary for true health equity.

Loading summary...

Transcript

A (0:01)

This is Drug Story. I'm Thomas Goetz. A few years ago, I wrote a book called the Remedy. It was about tuberculosis, which is the deadliest infectious disease in human history. The bacteria that causes TB was first identified in 1882 by a German physician and researcher named Robert Koch. Koch was an amazing scientist, but quite a flawed human being. This discovery was perhaps the biggest breakthrough in the history of medicine up to that time. Because tuberculosis was a horrible disease in the US and other countries, TB was the leading cause of death. At the time, more people died of TB than heart disease or cancer or any non infectious disease. So to finally know what caused tb, a germ, well, that seemed like the first step to towards a cure. Koch's discovery got people hoping that it might be possible to actually vanquish this most deadly disease in human history. And sure enough, a few years after he discovered the bacteria that caused tb, Robert Koch announced that he had also discovered the cure, the remedy. Well, not to spoil the ending of my own book, but in actual fact, Koch's remedy did not work. It was debunked by none other than Arthur Conan Doyle, who was at the time also a doctor and a writer. He had just created a detective character called Sherlock Holmes. This is a crazy story. It's an amazing tale of science and innovation and ego. That's kind of why I wrote a whole book about it. And it's still worth reading, even now that you kind of know the ending. Well, it would actually take more than half a century before a true cure for tuberculosis came along. And that was streptomycin. It was an antibiotic that was discovered in 1943. Streptomycin works. It kills the bacteria that causes TB. And since then, several other antibiotics have been discovered that work even better. Because the thing about TB is it changes. The bacteria adapts to the drugs. It finds a way to evolve around the antibiotic and keep going. Since Koch's discovery of the bacteria in 1882, more than a billion people have died of the disease, even with antibiotics. Even today, people die of tb. More than a million people a year. In fact, they're mostly in Asia, Africa and India. These people die even though there are drugs that work that cure the disease. Well, in today's episode of Drug Story, I'm actually going to let someone else tell that story. John Green, the author of another book about TB called Everything Is Tuberculosis, you may have heard of it. It's been a bestseller for months. And he says some very nice things about my book in there, which I appreciate. So today I'm handing over Drug Story to John Green and the excellent journalist Dan Weissman. He's host of the NPR podcast An Arm and a Leg. In this episode of An Arm and a Leg, Dan does a great job explaining something that we've touched on several times here on Drug Story. The idea of patents for drugs, how that system went off the rails and how patents for a very effective drug for TB kept on being approved and how people with TB kept on dying. I think you're going to enjoy this episode a lot. Here it is.

B (5:25)

I mean that is a super fun story that we're going to get into how a self proclaimed nerd raised an Internet posse to influence a global pharma giant into doing something pretty decent sounding. We're definitely going to tell that story, but that story is Just a first impression because the whole thing is bigger and way more complicated, as John Green would tell you. As he told me, he was just adding his bit to a global movement, to advocates and lawyers in places like India, for instance, that have been doing the heavy, heavy lifting for years. And of course, to understand any of this, we're going to have to get into how pharma companies use drug patents and what it means. And that is part of where this story comes home. As John Green mentioned in his video, the story of this tuberculosis drug wouldn't normally draw a lot of attention in the U.S. tB isn't one of our top health issues, but the mechanisms at play with this tuberculosis drug, the patent games, are some of the same mechanisms that make so many drugs here so expensive. Drugs like Humira and insulin and pretty much everything else. And here's what's actually the most interesting part behind the first impression version of this story. Nerds in the US rally their online posse for people in what's called the Global South. There's a story about people and ideas from the Global south coming here to save the US from our own messed up drug patent system. Because they've figured out that unless we save ourselves, they're screwed too. This is an arm and a leg, a show about why healthcare costs so freaking much and what we can maybe do about it. I'm Dan Weissman, I'm a reporter, I like to challenge. So our job on this show is to take one of the most enraging, terrifying, depressing parts of American life and bring you something entertaining, empowering and useful. And so let's start with John Green. YouTuber. John and his brother Hank were among the people who invented the idea of being a professional, quote unquote creator on the Internet. Maybe kind of by accident at first, but they were hugely successful at it. In 2007 they started posting video messages to each other on this still kinda new website called YouTube. They thought a few hundred people might be interested if they kept it up for a year. And then Hank posted a song about waiting for the last Harry Potter book to come out.